Skip to main content

Market Overview

UPDATE: Mizuho Securities Reiterates On Auxilium Pharmaceuticals On Cost Savings/Taxes

Share:

In a report published Wednesday, Mizuho Securities analyst Mario Corso reiterated a Buy rating on Auxilium Pharmaceuticals (NASDAQ: AUXL), and raised the price target from $33.00 to $37.00.

In the report, Mizuho Securities USA noted, “Last night's ENDP bid of $28.10/AUXL share is below 2014 high and our standalone valuation, implying term revisions likely. Inclusion of restructuring cost savings/QLT tax benefits raised numbers dramatically in 2015+, with our 2014 slightly lower on revenue conservatism, DCF target to $37 from $33. We do not expect major negatives from Wednesday's testosterone FDA panel, but CV studies could be requested and/or approved indication narrowed, but little effect with Testim now <10% of 2015 revenue vs. 50% in 2013, reflecting focus on growth drivers Xiaflex, Stendra,”

Auxilium Pharmaceuticals closed on Tuesday at $21.52.

Latest Ratings for AUXL

DateFirmActionFromTo
Oct 2014MizuhoDowngradesBuyNeutral
Oct 2014MKM PartnersDowngradesBuyNeutral
Sep 2014RBC CapitalDowngradesOutperformSector Perform

View More Analyst Ratings for AUXL
View the Latest Analyst Ratings

 

Related Articles (AUXL)

View Comments and Join the Discussion!

Posted-In: Mario Corso Mizuho Securities USAAnalyst Color Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
FOARaymond JamesInitiates Coverage On15.0
TZOONoble Capital MarketsUpgrades18.0
IMAXWedbushUpgrades26.0
EIGBoenning & ScattergoodUpgrades49.0
HUYA86 ResearchUpgrades22.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com